Search clinical trials for: BNP7787

Total 4 results

BioNumerik Pharmaceuticals, Inc.
Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of...

Completed

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

Breast Neoplasms | Breast Diseases | Metastases, Neoplasm
BioNumerik Pharmaceuticals, Inc.
Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of...

Completed

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

Non-small Cell Lung Cancer

Poland, Russian Federation, Bulgaria, United States, Romania, Ukraine
Lantern Pharma Inc.

Recruiting

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (HARMONIC)

Carcinoma, Non-Small-Cell Lung | Adenocarcinoma of Lung

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Anemia | Lung Cancer | Neutropenia | Drug/Agent Toxicity by Tissue/Organ

United States

3

Subscribe